Vinge advises Active Biotech in relation to directed new share issue
April 04, 2013
In March this year, Active Biotech AB (publ) conducted a directed new share issue to Investor AB (publ) pursuant to which Active Biotech procured SEK 270 million.
Vinge’s team consisted of partner Erik Sjöman and associate Christian Lindhé.
Vinge has advised Orexo AB (publ) in connection with a partially guaranteed rights issue of approximately SEK 250 million before transaction costs, subject to approval by an extraordinary general meeting.
Vinge has advised Axcel VII and Accru Partners in connection with the acquisitions of R3 Revisionsbyrå AB, Adrevicor Halland AB, Trevi Revision AB and Adrevicor Stockholm AB.
Vinge has advised Folksam Group in connection with two investments totalling SEK 7.2 billion in infrastructure funds managed by Copenhagen Infrastructure Partners and Arjun Infrastructure Partners, respectively.
